[18F]FLT PET for diagnosis and staging of thoracic tumours

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 10, 2003, Pages 1407-1412

  Dittmann, Helmut ^a   Dohmen, Bernhard Matthias ^a   Paulsen, Frank ^a   Eichhorn, Kai ^a   Eschmann, Susanne Martina ^a   Horger, Marius ^a   Wehrmann, Manfred ^a   Machulla, Hans Juergen ^a   Bares, Roland ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Fluorodeoxyglucose; Fluorothymidine; Positron emission tomography; Thoracic tumours; Thymidine kinase

Indexed keywords

3' DEOXY 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; IMAGING; MALE; POSITRON EMISSION TOMOGRAPHY; THORAX TUMOR; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; METASTASIS; METHODOLOGY; MIDDLE AGED; NEOPLASM; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

ADULT; AGED; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THORACIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0141996517     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1257-3     Document Type: Article

References (10)

1. Costa A, Silvestrini R, Mochen C, Lequaglie C, Boracchi P, Faranda A, Vessecchia G, Ravasi G. P53 expression, DNA ploidy and S-phase cell fraction in operable locally advanced non-small-cell lung cancer. Br J Cancer 1996; 73:914-919.
2. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, Ostrander M, Lang SA, Muchmore E, Chou TC. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1992; 36:808-818.
3. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336.
4. Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, Hogg A, Ball DL. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001; 19:111-118.
5. 18F]FLT; portrait of a proliferation marker. Eur J Nucl Med Mol Imaging 2002; 29:165-169.
6. 18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331-3334.
7. 18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8:3315-3323.
8. Shields AF, Grierson JR, Muzik O, Stayanoff JC, Lawhom-Crews JM, Obradovich JE, Mangner TJ. Kinetics of 3′-deoxy3′ -[F18]fluorothymidine uptake and retention in dogs. Mol Imaging Biol 2002; 4:83-89.
9. Dohmen BM, Wei R, Grierson J, Shields AF, Reimold M, Machulla HJ, Bares R. FLT-Speicherung in malignen Tumoren: Erste Ergebnisse einer Pilotstudie. Nucl Med 2000; 39:A44.
10. Gasinska A, Kolodziejski L, Biesaga B. Tumour cell kinetics as prognostic factor in surgically-treated non-small cell lung cancer. Lung Cancer 1997; 18:159-170.